BKBuddheera Bandara Wm Kumburegama

Buddheera Bandara Wm Kumburegama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Buddheera Bandara Wm Kumburegama has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Liver support systems for adults with acute liver failure

    by Arturo J Martí-Carvajal, Buddheera Bandara Wm Kumburegama, Dimitrinka Nikolova, Chavdar S Pavlov, Ezequiel Mauro, Lise Lotte Gluud, Diana Monge Martín, Jian Ping Liu, Susana Nicola, Gabriella Comunián-Carrasco, et al.

    Acute liver failure (ALF) is a life-threatening condition, characterised by serious damage to the liver cells and function. The aetiology of ALF determines the prognosis, and without immediate care or liver transplantation, people with ALF will develop life-threatening complications and die. Liver support systems are used as a bridge therapy to provide detoxification and restore liver function until either functional recovery occurs or a liver becomes available for transplantation. Liver support systems have continued to be used despite conflicting results of randomised clinical trials (RCTs). To assess the benefits and harms of liver support systems plus standard medical care versus standard medical care for adults with acute liver failure. We identified trials through manual and electronic searches in The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, LILACS, Science Citation Index Expanded, and Conference Proceedings Citation Index - Science. We also searched reference lists, trials registers, other sources, and contacted trial authors to identify trials for inclusion in the review. The latest search date was 10 July 2025. We included RCTs (published as abstracts or full-text articles) with a parallel-group design. We included the trials irrespective of the publication language and year, country of performance, or reported outcomes. The trials compared liver support systems plus standard medical care versus standard medical care. We included trials in adults ≥ 18 years old, of any sex, ethnicity, or race, diagnosed with ALF (including previous definitions) and irrespective of aetiology. We excluded trials with mixed populations where participants with ALF were < 10 % of the total number of participants; quasi-randomised trials and other observational studies. Critical outcomes were: all-cause mortality by day 28, all-cause mortality, serious adverse events (measured by the total number of people with one or more events), and the proportion of people with liver transplantation. Important outcomes included health-related quality of life, hepatic encephalopathy, and multi-organ failure (measured by the total number of events, including people who needed liver transplantation). Except for all-cause mortality by day 28, we planned to assess the remaining outcomes at their maximal follow-up. We assessed the risk of bias with the outcome-based RoB 2 tool. We judged the overall bias risk of each outcome result using the intention-to-treat principle. We resolved disagreements through discussion. We followed the Methodological Expectations for Cochrane Intervention Reviews when conducting the review, and PRISMA 2020 for the reporting. We conducted meta-analyses of available data for each outcome at the prespecified time points. We analysed dichotomous data using the risk ratio (RR) and the random-effects model, and calculated the rate ratio from the total number of events in the separate groups of a trial, with a set-up of contrast-level data and the inverse variance method. For both types of analyses, we used a 95% confidence interval (CI). We assessed the certainty of evidence of seven prespecified outcome results using the five GRADE domains (risk of bias, heterogeneity, indirectness, imprecision using a minimally contextualised approach, and publication bias). We included 11 parallel-group RCTs with 681 randomised participants (342 to the experimental group and 339 to the control intervention groups). Two of the trials were only published as abstracts. In the trials reporting on age, there were a few participants (≤ 18 years old) with inseparable data (age range: 10 to 69 years), whom we included in the analyses. The trials compared artificial liver support systems (eight trials) or bioartificial liver support systems (three trials) plus standard treatment and care versus standard treatment and care alone in people with ALF. They were conducted in Europe (Austria, Germany, Denmark, Finland, France, the UK), India, and the USA. The trial participants were treated in intensive care units. The maximal follow-up for all-cause mortality and hepatic encephalopathy was 90 days; for serious adverse events, liver transplantation, and multi-organ failure, it was 360 days. We downgraded the certainty of evidence to very low due to risk of bias and imprecision in all outcome results, and heterogeneity in the two mortality outcome results. Liver support systems may have little to no effect on all-cause mortality by day 28 (RR 0.83, 95% CI 0.58 to 1.19; I² = 66%; 9 studies, 539 participants; very low-certainty evidence), all-cause mortality at maximal follow-up (RR 0.82, 95% CI 0.63 to 1.07; I² = 52%; 11 studies, 681 participants; very low-certainty evidence), on the number of serious adverse events (Rate ratio 0.93, 95% CI 0.81 to 1.07; I² = 0%; 11 studies, 681 participants; very low-certainty evidence), and on the proportion of people with liver transplantation (RR 1.03, 95% CI 0.87 to 1.21; I² = 0%; 5 studies, 519 participants; very low-certainty evidence). No trial included health-related quality of life as an outcome. The evidence is very uncertain about the effect of liver support systems on hepatic encephalopathy (RR 0.40, 95% CI 0.16 to 1.04; I² = 0%; 2 studies, 34 participants; very low-certainty evidence). Liver support systems may have little to no effect on the number of multi-organ failures (Rate ratio 0.92, 95% CI 0.72 to 1.18; I² = 0%; 6 studies, 501 participants; very low-certainty evidence). Five trials had no for-profit funding, four trials declared full or partial for-profit funding and two trials did not declare funding. One study is awaiting classification. We found no ongoing randomised clinical trials. The trials assessed experimental liver support systems in adults with ALF. Based on very low-certainty evidence, we are very uncertain about the effects...


  • Open Access

    Direct-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies

    by Buddheera W. M. B. Kumburegama, Andreas T. Kristensen, Goran Bjelakovic, Dimitrinka Nikolova, Mark A. Asante, Milica Bjelakovic, Ronald L. Koretz, Mithuna M. Balakumar, Martin E. Michelsen, Sarah L. Klingenberg, et al.

    Chronic hepatitis C virus infection presents a substantial global health burden, frequently resulting in severe liver conditions. Hepatitis C virus (HCV) t


  • Open Access

    Direct-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies

    by Buddheera W.M.B. Kumburegama, Andreas T. Kristensen, Goran Bjelakovic, Dimitrinka Nikolova, Mark A. Asante, Milica Bjelakovic, Ronald L. Koretz, Mithuna M. Balakumar, Martin E. Michelsen, Sarah L. Klingenberg, et al.

    Background: Chronic hepatitis C virus infection presents a substantial global health burden, frequently resulting in severe liver conditions. Hepatitis C virus (HCV) therapy requires complex decision-making. Direct-acting antivirals (DAAs) offer a potential solution by targeting viral proteins to inhibit replication. Understanding DAAs real-world effectiveness and how they impact long-term outcomes beyond clinical trials is essential. We aim to comprehensively evaluate the benefits and harms of DAAs in individuals with chronic HCV infection, reported in observational studies. Methods: We will consider for inclusion prospective and retrospective observational studies with quasirandomised, cohort, case-control, controlled before-and-after, and cross-sectional designs. Our experimental interventions will be any class of DAAs available on the market or in development. DAAs could have been administered alone, in combination, or with other medical co-interventions. Our control interventions will be untreated chronic HCV conditions, with or without placebo. Participants will be adults, regardless of demographics, treatment history, or healthcare setting. Our primary outcomes will be participants experiencing hepatitis C-related morbidity or all-cause mortality, serious adverse events, and health-related quality of life. Secondary outcomes will include all-cause mortality, cirrhosis, variceal bleeding, hepato-renal syndrome, hepatocellular carcinoma, hepatic encephalopathy, non-serious adverse events, liver transplantation, lack of sustained virological response, histological improvement, and decreases in alanine aminotransferase and aspartate aminotransferase levels. We will apply search strategies to search MEDLINE, Embase, Web of Science, grey literature, and trial registers. We will use Covidence ® to screen the result, including citations. Individual double-data extraction will include study details and outcomes, with independent review authors resolving discrepancies. We will assess bias using the ROBINS-I tool. Meta-analyses will employ random-effects models for both dichotomous and continuous outcomes, assessing heterogeneity. Subgroup and sensitivity analyses will explore effect modifications and address missing data. Trial Sequential Analysis will control type I and type II errors. We will evaluate publication bias using funnel plots and Egger’s regression test and assess certainty of evidence using GRADE. Discussion: The findings will inform clinical decisions and benefit those affected by HCV, healthcare professionals, and policymakers. Systematic review registration: PROSPERO: CRD42023494844


  • Open Access

    Major mistakes or errors in the use of trial sequential analysis in systematic reviews or meta-analyses – the METSA systematic review

    by Christian Gunge Riberholt, Markus Harboe Olsen, Joachim Birch Milan, Sigurlaug Hanna Hafliðadóttir, Jeppe Houmann Svanholm, Elisabeth Buck Pedersen, Charles Chin Han Lew, Mark Aninakwah Asante, Johanne Pereira Ribeiro, Vibeke Wagner, et al.

    Background: Systematic reviews and data synthesis of randomised clinical trials play a crucial role in clinical practice, research, and health policy. Trial sequential analysis can be used in systematic reviews to control type I and type II errors, but methodological errors including lack of protocols and transparency are cause for concern. We assessed the reporting of trial sequential analysis. Methods: We searched Medline and the Cochrane Database of Systematic Reviews from 1 January 2018 to 31 December 2021 for systematic reviews and meta-analysis reports that include a trial sequential analysis. Only studies with at least two randomised clinical trials analysed in a forest plot and a trial sequential analysis were included. Two independent investigators assessed the studies. We evaluated protocolisation, reporting, and interpretation of the analyses, including their effect on any GRADE evaluation of imprecision. Results: We included 270 systematic reviews and 274 meta-analysis reports and extracted data from 624 trial sequential analyses. Only 134/270 (50%) systematic reviews planned the trial sequential analysis in the protocol. For analyses on dichotomous outcomes, the proportion of events in the control group was missing in 181/439 (41%), relative risk reduction in 105/439 (24%), alpha in 30/439 (7%), beta in 128/439 (29%), and heterogeneity in 232/439 (53%). For analyses on continuous outcomes, the minimally relevant difference was missing in 125/185 (68%), variance (or standard deviation) in 144/185 (78%), alpha in 23/185 (12%), beta in 63/185 (34%), and heterogeneity in 105/185 (57%). Graphical illustration of the trial sequential analysis was present in 93% of the analyses, however, the Z-curve was wrongly displayed in 135/624 (22%) and 227/624 (36%) did not include futility boundaries. The overall transparency of all 624 analyses was very poor in 236 (38%) and poor in 173 (28%). Conclusions: The majority of trial sequential analyses are not transparent when preparing or presenting the required parameters, partly due to missing or poorly conducted protocols. This hampers interpretation, reproducibility, and validity. Study registration: PROSPERO CRD42021273811